Viral Inactivation Market Report 2026

Viral Inactivation Market Overview

• Viral Inactivation market size has reached to $5.47 billion in 2025 • Expected to grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Rising Prevalence Of Infectious Diseases To Drive Market Growth • Market Trend: Advancing Safety And Efficiency With Next-Generation Viral-Clearance Solutions • North America was the largest region in 2025 and Asia-pacific is the fastest growing region.

What Is Covered Under Viral Inactivation Market?

Viral inactivation refers to the process of inactivation of viral contamination by exposing the bioprocess fluid to environments that denature the viral protein yet retain the active ingredient of the product. Viral inactivation is most commonly used in blood plasma processing and monoclonal antibody processing. The main products of viral inactivation are kits and reagents, systems, and services. The solvent detergent method refers to the process that involves damage to the lipid membrane of encapsulated viruses and causes their inactivation. The solvent detergent method is used in plasma to safely render all lipid-enveloped viruses. The viral inactivation typically has solvent detergent method, pH adjustment method, pasteurization, and other methods that are applied in vaccines and therapeutics, tissues and tissue products, blood and blood products, and other applications. The end-users include pharmaceutical and biotechnology companies, contract research organizations, blood banks, hospitals, academic research institutes, and other end users.

What Is The Viral Inactivation Market Growth Forecast?

The viral inactivation market size is expected to see rapid growth in the next few years. It will grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to increasing demand for biologics and biosimilars, rising investments in advanced bioprocessing facilities, growing focus on continuous manufacturing, increasing adoption of automated quality control systems, expansion of vaccine production pipelines. Major trends in the forecast period include increasing adoption of automated viral inactivation systems, rising demand for validated virus safety processes, growing use of continuous flow inactivation methods, expansion of single-use bioprocessing solutions, enhanced focus on process reproducibility and compliance.

What Is The Driver Of The Viral Inactivation Market?

Growing instances of various infectious diseases are expected to propel the growth of the viral inactivation market, going forward. Infectious diseases refer to the conditions that transmit from one individual to another, via polluted foods and beverages, and through pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation is widely applicable in human disease-control programs to inactivate viruses using physical and chemical disinfectants to prevent the spread of contagious viral infections, resulting in the growth of the viral inactivation market. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency of the United States, the number of cases of tuberculosis increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. The rate also increased from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. Therefore, the growing instances of various infectious diseases are driving the growth of the viral inactivation industry.

Key Players In The Global Viral Inactivation Market

Major companies operating in the viral inactivation market are Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation And Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG

Global Viral Inactivation Market Trends and Insights

Major companies operating in the viral inactivation market are focusing on incorporating advanced viral-clearance technologies to enhance biologic safety, regulatory compliance, and process efficiency. These technologies, which inactivate viruses through chemical, physical, or filtration-based mechanisms, enable capabilities such as log-reduction validation, regulatory-compliant viral safety assurance, and faster decision-making in biologics development. For instance, in May 2025, Northway Biotech, a Lithuania-based contract development and manufacturing organization (CDMO), launched Full-Service Viral Clearance Studies (VCS), an advanced viral-clearance solution designed to accelerate safety validation for protein biologics and gene therapies, featuring multiple identical BSL-2 laboratories for high-throughput workflows, BSL-3 testing capabilities, and delivery of full regulatory-compliant viral clearance results in under 10 weeks, significantly faster than industry norms. This offering improves development speed, cost control, and regulatory readiness for biopharma clients.

What Are Latest Mergers And Acquisitions In The Viral Inactivation Market?

In November 2025, Croda International Plc, a UK-based specialty-ingredients company, entered into a strategic partnership with Amino GmbH. With this collaboration, Croda and Amino aim to expand global access to high-purity amino acids for pharmaceutical formulation and biomanufacturing, enabling faster therapy development, consistent regulatory-grade raw-material availability, improved sustainability, and enhanced manufacturing efficiency. Amino GmbH is a Germany-based manufacturer of pharmaceutical-grade amino acids and brings advanced precision-manufacturing expertise tailored for pharma and nutritional applications.

What Defines the Viral Inactivation Market?

The viral inactivation market includes revenues earned by chemical viral inactivation and radiation viral inactivation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Inactivation Market Report 2026?

The viral inactivation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral inactivation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.